CN Patent

CN104523630B — 一种奈韦拉平片剂

Assigned to Shandong New Time Pharmaceutical Co Ltd · Expires 2017-08-25 · 9y expired

What this patent protects

本发明属于医药技术领域，涉及一种奈韦拉平片剂，所述片剂含有奈韦拉平、有机酸和β‑环糊精，所述奈韦拉平、有机酸混合进行气流粉碎，用辛酸癸酸聚乙二醇甘油酯制粒后，然后与β‑环糊精以及药学上可接受的辅料混合均匀，压片而成。本发明与现有技术相比，工艺简单，溶出速度快，并且药物在四种常规溶出介质中均能够完全溶出。

USPTO Abstract

本发明属于医药技术领域，涉及一种奈韦拉平片剂，所述片剂含有奈韦拉平、有机酸和β‑环糊精，所述奈韦拉平、有机酸混合进行气流粉碎，用辛酸癸酸聚乙二醇甘油酯制粒后，然后与β‑环糊精以及药学上可接受的辅料混合均匀，压片而成。本发明与现有技术相比，工艺简单，溶出速度快，并且药物在四种常规溶出介质中均能够完全溶出。

Drugs covered by this patent

Patent Metadata

Patent number
CN104523630B
Jurisdiction
CN
Classification
—
Expires
2017-08-25
Drug substance claim
No
Drug product claim
No
Assignee
Shandong New Time Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.